Sharing US Drug Patents with Neglected Patients: A Scientist’s View
"Instead of re-hashing old debates about patents, patients and profits, forward-looking pharmaceutical executives should consider new ways of ensuring that medicines reach all patients who need them," writes John Erickson, one of the researchers who discovered the HIV medicine recently licensed by the National Institutes of Health to the Medicines Patent Pool.

Daniele Dionisio writes: The current break-through of multinational drug corporations in India couples with the protectionist policies pursued by the US and EU and with India’s obligations as a WTO member. Taken together, these realities mean a heavy threat to India’s freedom as independent provider of lifesaving, affordable and state-of-the-art antiretroviral medicines to the resource-limited countries.
The Intellectual Property Watch Monthly Edition features top news on international IP policymaking, the latest on who is coming and going in the international IP community, news briefs and more. The October edition is now available for subscribers at: http://www.ip-watch.org/user/newsletter.
A leading indigenous negotiator for a UN protocol on biodiversity access and benefit sharing says the process will likely yield a highly diluted, rights-poor protocol and that Indigenous Peoples' negotiating leverage is slipping.